Background After long-term androgen deprivation therapy, 25–30% prostate cancer (PCa)
acquires an aggressive neuroendocrine (NE) phenotype. Dysregulation of YAP1, a key …

Objective: Yes associated protein 1 (YAP1) is a member of the Hippo pathway, acting as a
transcriptional coactivator. To elucidate the role of YAP1 and phosphorylated (p) YAP1 in …

The transcriptional coactivator YAP1 controls the balance between cell proliferation and
apoptosis. YAP1 overexpression is linked to poor prognosis in many cancer types, yet its …

Yes-associated protein (YAP) is an effector of the Hippo tumor suppressor pathway. The
functional significance of YAP in prostate cancer has remained elusive. In this study, we first …

Neuroendocrine prostate cancer (NEPC) is a rare but aggressive histologic variant of
prostate cancer that responds poorly to androgen deprivation therapy. Hybrid NEPC …

The transcriptional co-activator Yes-associated protein 1 (YAP1), a key nuclear effector of
the Hippo pathway, is a potent oncogene, and yet, the interaction between YAP1 and …

Abstract The Yes Associated Protein 1 (YAP1) is a transcriptional cofactor negatively
regulated by Hippo Pathway. The dysregulation of the pathway has been shown to have a …

The Hippo pathway regulates and contributes to several hallmarks of prostate cancer (PCa).
Although the elucidation of YAP function in PCa is in its infancy, emerging studies have shed …

Yes-associated protein 65 (YAP65) has been implicated as an oncogene, and its expression
is increased in human cancer. Previous studies have demonstrated that alterations in YAP …

Background Yes-associated protein 1 (YAP 1), the nuclear effector of the Hippo pathway, is
a key regulator of organ size and a candidate human oncogene in multiple tumors …